Anti-inflammatory effect of alpha, beta-Amyrin, a pentacyclic triterpene from Protium heptaphyllum in rat model of acute periodontitis.
This study was aimed to evaluate the anti-inflammatory potential of triterpene alpha, beta-amyrin in rats on acute phase periodontitis. Periodontitis was induced by ligature placement around the maxillary right second molar tooth. Rats (n = 8/group) were pretreated with alpha, beta-amyrin (5 and 10 mg/kg, p. o.), two hours before the induction of periodontal inflammation. Sham-operated and positive controls (lumiracoxib and dexamethasone) were included. Six hours later, plasma levels of TNF-alpha were analysed. Rats were sacrificed at 24 h, and the gingival tissue analysed for myeloperoxidase (MPO) and thiobarbituric acid-reactive substances (TBARS), as measures of neutrophil influx and lipid-peroxidation, respectively alpha, beta-Amyrin as well as dexamethasone significantly inhibited the periodontitis-associated increases of TNF-alpha, and the gingival MPO and TBARS. alpha, beta-Amyrin effect was more prominent at 5 mg/kg. Lumiracoxib manifested varied influence on the studied parameters. These results provide evidence to show that alpha, beta-Amyrin retards acute inflammation in rat model of periodontitis and warrant further study on its efficacy to prevent chronic periodontitis-associated bone loss.
Holanda Pinto
S A
SA
Department of Physiology and Pharmacology, Post-Graduation Programme in Medical Sciences, Faculty of Medicine, Federal University of Ceara, POB 3157, Rua Cel Nunes de Melo, 1127, Porangabussu, 60430-270, Fortaleza, CE, Brazil.
Pinto
L M S
LM
Cunha
G M A
GM
Chaves
M H
MH
Santos
F A
FA
Rao
V S
VS
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D029403:Burseraceae / Q000737:chemistry*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004195:Disease Models, Animal; D005881:Gingiva / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005891:Gingivitis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D007536:Isomerism; D008297:Male; D015394:Molecular Structure; D020556:Neutrophil Infiltration / Q000187:drug effects; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D018384:Oxidative Stress / Q000187:drug effects; D053978:Pentacyclic Triterpenes / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D010518:Periodontitis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D053978:Pentacyclic Triterpenes; D017392:Thiobarbituric Acid Reactive Substances; D014409:Tumor Necrosis Factor-alpha; D004008:Diclofenac; D009828:Oleanolic Acid; D003907:Dexamethasone; D009195:Peroxidase; C036380:beta-amyrin; C473384:lumiracoxib